Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

Updated

Results posted for phase 1 trial of Autologous T-regulatory lymphocytes

Original source

Phase 1 trial of Autologous T-regulatory lymphocytes completesClinicalTrials.gov · 17 June 2026 (opens in a new tab)

1 further copy of this report was also considered.

Trial at a glance

Status
Completed
Phase
Phase 1
Intervention
Autologous T-regulatory lymphocytes (biological)
Enrolment
3 participants (actual)
Site
the United States
Sponsor
The Methodist Hospital Research Institute
Registration
NCT03241784

Compass reports what the trial registry states. A trial being registered, recruiting or completed is not evidence that a treatment works.

This completed Phase 1 interventional study tested autologous T-regulatory lymphocytes and interleukin-2 in 3 people with amyotrophic lateral sclerosis at sites in the United States. Results have been posted, which is the latest change to the registry record.

Why this matters

The study is completed and results have been posted, so this research record now includes results information for people tracking ALS/MND research. The registry fields do not provide details of those results.

Trial updates

Results posted17 June 2026

  1. 17 June 2026Study completed

Compass began tracking this trial’s registry record on the date of its first update above. Changes before then are not listed.

Summarised by Compass 30 August 2026 · updated 30 August 2026 · reported from the United States

This summary was generated by AI from the reporting behind this development, not from the single article shown first. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?